236 related articles for article (PubMed ID: 31189476)
1. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study.
Sanagoo A; Jouybari L; Koohi F; Sayehmiri F
BMC Neurol; 2019 Jun; 19(1):123. PubMed ID: 31189476
[TBL] [Abstract][Full Text] [Related]
2. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
Fishbein NS; Vranceanu AM; Mace RA
J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
[TBL] [Abstract][Full Text] [Related]
4. Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis.
Mace RA; Doorley J; Bakhshaie J; Cohen JE; Vranceanu AM
J Neurooncol; 2021 Nov; 155(2):125-132. PubMed ID: 34570301
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J
JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983
[TBL] [Abstract][Full Text] [Related]
6. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
[TBL] [Abstract][Full Text] [Related]
7. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis.
Pietrzykowski MO; Vranceanu AM; Macklin EA; Mace RA
Qual Life Res; 2024 May; 33(5):1233-1240. PubMed ID: 38214851
[TBL] [Abstract][Full Text] [Related]
8. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis.
Wei G; Farooq J; Kumar A
Dermatol Ther; 2021 Jan; 34(1):e14613. PubMed ID: 33258517
[TBL] [Abstract][Full Text] [Related]
9. Mind-Body Therapy via Videoconferencing in Patients With Neurofibromatosis: Analyses of 1-Year Follow-up.
Lester EG; Gates MV; Vranceanu AM
Ann Behav Med; 2021 Feb; 55(1):77-81. PubMed ID: 32421171
[TBL] [Abstract][Full Text] [Related]
10. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
11. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.
Vranceanu AM; Riklin E; Merker VL; Macklin EA; Park ER; Plotkin SR
Neurology; 2016 Aug; 87(8):806-14. PubMed ID: 27449066
[TBL] [Abstract][Full Text] [Related]
12. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.
Vranceanu AM; Merker VL; Park ER; Plotkin SR
J Neurooncol; 2015 Apr; 122(2):219-28. PubMed ID: 25663248
[TBL] [Abstract][Full Text] [Related]
13. The impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis.
Freier A; Lawson McLean AC; Loeschner D; Rosahl SK; Kruse J
Sci Rep; 2024 Mar; 14(1):6934. PubMed ID: 38521834
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life of patients with cystic fibrosis assessed by the SF-36 questionnaire.
Uchmanowicz I; Jankowska-Polańska B; Wleklik M; Rosinczuk-Tonderys J; Dębska G
Pneumonol Alergol Pol; 2014; 82(1):10-7. PubMed ID: 24391066
[TBL] [Abstract][Full Text] [Related]
15. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial.
Lester E; DiStefano S; Mace R; Macklin E; Plotkin S; Vranceanu AM
Gen Hosp Psychiatry; 2020; 62():72-78. PubMed ID: 31841875
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.
Ferner RE; Thomas M; Mercer G; Williams V; Leschziner GD; Afridi SK; Golding JF
Health Qual Life Outcomes; 2017 Feb; 15(1):34. PubMed ID: 28193237
[TBL] [Abstract][Full Text] [Related]
17. Home practice and quality of life among patients with neurofibromatosis randomized to a mind-body intervention.
Funes CJ; Zale EL; Luberto CM; Vranceanu AM
Complement Ther Med; 2019 Feb; 42():114-118. PubMed ID: 30670227
[TBL] [Abstract][Full Text] [Related]
18. Diverse learners: learning disabilities and quality of life following mind-body and health education interventions for adults with neurofibromatosis.
Kanaya MR; Greenberg J; Bakhshaie J; Vranceanu AM
J Neurooncol; 2024 Apr; 167(2):315-322. PubMed ID: 38409461
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in Iranian elderly population using the SF-36 questionnaire: systematic review and meta-analysis.
Doosti-Irani A; Nedjat S; Nedjat S; Cheraghi P; Cheraghi Z
East Mediterr Health J; 2019 Jan; 24(11):1088-1097. PubMed ID: 30701524
[TBL] [Abstract][Full Text] [Related]
20. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
